earnings
confidence high
sentiment neutral
materiality 0.70
Amarin Q2 2026 net revenue $42.2M (-42% YoY); operating loss narrows to $12.0M; cash grows to $314.6M
AMARIN CORP PLCUK
- Total net revenue $42.2M, down 42% YoY due to absence of $25M Recordati upfront payment and generic pressure on U.S. VASCEPA pricing.
- Operating expenses fell 59% to $27.0M; excluding restructuring, down 38% YoY, completing $70M annual cost savings initiative.
- Operating loss improved to $12.0M from $16.0M; net loss $7.7M vs $14.1M; cash grew to $314.6M, debt-free.
- Global in-market demand for VASCEPA/VAZKEPA rose 59% YoY; U.S. IPE market share increased to 48% from 43%.
- Company expects continued international growth, consistent U.S. volumes, and ~10% cash growth by year-end 2026.